Biotech: Page
-
Courtesy of Vertex Pharmaceuticals
Vertex, startup Orna to partner on gene editing research
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.
By Delilah Alvarado • Jan. 7, 2025 -
Getty Images
Metsera reveals data supporting long-acting obesity shot
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug as a future threat to weight loss medicines from Novo Nordisk and Eli Lilly.
By Jonathan Gardner • Jan. 7, 2025 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Courtesy of Novo Holdings
Orbis raises $93M to turn popular biologics into pills
The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against “validated blockbuster biologic targets.”
By Gwendolyn Wu • Jan. 6, 2025 -
Getty Images
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.
By BioPharma Dive staff • Jan. 2, 2025 -
Getty Images
Ionis gets a milestone approval; Another top FDA official to step down
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.
By BioPharma Dive staff • Dec. 20, 2024 -
Getty Images
A venture firm breathes new life into an old NGM drug
A startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare condition.
By Gwendolyn Wu • Dec. 19, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.
By Jacob Bell • Dec. 19, 2024 -
Kyodo/Newscom
Ottimo raises $140M to compete in chase for new type of cancer drug
Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and VEGF-blocking cancer treatments.
By Ben Fidler • Dec. 19, 2024 -
Getty Images
Tessera gets sickle cell funding; Corvus shares slide on eczema data
The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.
By BioPharma Dive staff • Dec. 18, 2024 -
K_E_N via Getty Images
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
“Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The company plans to use its new funds to get to “proof of concept” for its medicines.
By Jacob Bell • Dec. 18, 2024 -
Jacob Bell/BioPharma Dive
Jazz to search for new chief as CEO plans retirement
Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its search within one year.
By Ned Pagliarulo • Dec. 16, 2024 -
Spencer Platt via Getty Images
Edgewise weighs fast approval path for muscular dystrophy drug
The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.
By Ned Pagliarulo • Dec. 16, 2024 -
Getty Images
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.
By BioPharma Dive staff • Dec. 16, 2024 -
Permission granted by Maat Pharma
Sponsored by MaaT PharmaCould the gut microbiome hold the key to fighting cancer?
MaaT Pharma is at the forefront of innovation in this field, striving to achieve the first-ever approval of a microbiome-driven immunomodulator in oncology.
Dec. 16, 2024 -
Getty Images
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that deny coverage of Qalsody because it’s “experimental and investigational.”
By Jacob Bell • Dec. 13, 2024 -
Getty Images
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi.
By BioPharma Dive staff • Dec. 13, 2024 -
Courtesy of AbbVie
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi.
By Ned Pagliarulo • Dec. 13, 2024 -
Permission granted by Editas Medicine
Gene editingEditas to lay off staff after search for sickle cell partner comes up empty
The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug candidate reni-cel.
By Ned Pagliarulo • Updated Dec. 13, 2024 -
Andrew Harnik via Getty Images
‘Research that’s desperately needed’: White House conference spotlights women’s health
“Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who attended Wednesday’s event.
By Delilah Alvarado • Dec. 12, 2024 -
Getty Images
Q32 Bio battered by study failure of immune drug
Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.
By Kristin Jensen • Dec. 11, 2024 -
Getty Images
BenevolentAI restructures; Lilly preps $15B buyback program
The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.
By BioPharma Dive staff • Updated Dec. 17, 2024 -
Getty Images
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million from a broad syndicate.
By Gwendolyn Wu , Ned Pagliarulo • Dec. 11, 2024 -
Courtesy of UniQure
UniQure shares soar on chance of speedy approval for Huntington’s therapy
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an accelerated approval application.
By Jacob Bell • Dec. 10, 2024 -
Permission granted by Dimension
Dimension gets $500M to bankroll biotech’s convergence with tech
The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team versed in both computing and life sciences and concentrating resources on a smaller number of bets.
By Ben Fidler • Dec. 9, 2024 -
Permission granted by Greater Phoenix Economic Council (GPEC)
Sponsored by Greater Phoenix Economic Council (GPEC)Why bioscience and healthcare innovators are looking to Phoenix
When Mayo Clinic was evaluating locations to build a biotechnology innovation hub, the Greater Phoenix region emerged as the ideal option.
Dec. 9, 2024
Previous
